Figure 2. Effect of pre-treatment with yuzu (100 mg/kg/day) or hesperidin (HSP, 30 mg/kg/day) on cardiac dysfunction.

(A) Representative M-mode echocardiograms. (B–E) Echocardiographic measurement of left ventricular (LV) internal dimensions at both systole and diastole (LVIDs and LVIDd, respectively), LV ejection fraction, and heart weight (HW) to body weight (BW) ratio. Data are expressed as mean ± SEM; *p<0.05 vs. sham; #p<0.05 vs. vehicle (permanent occlusion, PO). n = 10–13.